Cervical cancer is almost always caused by a persistent infection with a high-risk human papillomavirus (HPV), which usually takes more than 10 years to turn healthy cells into cancer. It is largely preventable through HPV vaccination and screening: in France, a smear test from 25 to 29, then an HPV test every 5 years from 30 to 65. Treatment, with surgery or chemoradiotherapy, depends on the stage.
Cervical cancer is a gynaecological cancer that is largely preventable (see our Gynaecological cancer care page). The cervix is the lower part of the uterus, which opens into the vagina. Most cancers start in the transformation zone, between the outer part of the cervix (ectocervix) and the cervical canal (endocervix).
The sequence of events is well understood:
This long delay gives screening time to find and treat abnormal cells before cancer develops. The two main types are squamous cell carcinoma (the most common) and adenocarcinoma.
In France, the national screening programme covers all women aged 25 to 65 who have not had a total hysterectomy, whether or not they are vaccinated. The guidelines of the French National Authority for Health (HAS) are as follows:
| Age | First-line test | Interval if normal |
|---|---|---|
| Under 25 | No routine screening | — |
| 25 to 29 | Cytology (smear test) | 2 smears one year apart, then every 3 years if both are normal |
| 30 to 65 | High-risk HPV test | Every 5 years (first test 3 years after the last normal smear) |
| Over 65 | End of the national screening programme | — |
After the age of 30, the HPV test performs better than the smear: follow-up of four large European trials showed it gave 60 to 70% more protection against invasive cancer, which allows tests to be spaced 5 years apart. It is done on the same sample as the smear. From the age of 30, women who are not screened or not screened often enough may be offered a vaginal self-sampling kit. The procedure and results are explained in our article on the cervical smear test.
HPV vaccination, recommended in France between the ages of 11 and 14 for girls and boys, with catch-up vaccination up to the age of 26 inclusive, complements screening but does not replace it.
Precancerous changes and early cancers cause no symptoms: that is why screening must be done even when you feel well. Later on, the following may appear:
These symptoms often have a benign cause (ectropion, infection, polyp), but they always need a gynaecological examination, even if your last screening test was normal.
Diagnosis relies on a biopsy of the cervix, usually guided by colposcopy, and sometimes on a cone biopsy for very early lesions. Staging tests determine the FIGO stage:
Every case is discussed at a multidisciplinary team meeting (MDT), and the 2023 European ESGO/ESTRO/ESP guidelines advise treatment in specialist centres. Treatment depends mainly on the stage and size of the tumour.
| Situation | Usual treatment |
|---|---|
| Microinvasive cancer (stage IA) | Cone biopsy alone or simple hysterectomy, depending on the depth and whether blood or lymph vessels are involved. |
| Small tumour confined to the cervix (IB1, some IB2, IIA1) | Surgery: radical hysterectomy with assessment of the pelvic lymph nodes (sentinel node). In a young woman who wants to become pregnant, fertility-sparing surgery (trachelectomy) may be considered for small tumours. |
| Large or locally advanced tumour (IB3, IIA2 to IVA) | Concurrent chemoradiotherapy (external radiotherapy and cisplatin-based chemotherapy), followed by brachytherapy. |
| Metastatic or recurrent disease | Chemotherapy, often combined with targeted therapy and immunotherapy, sometimes radiotherapy or surgery. |
For radical hysterectomy, an open approach (laparotomy) is recommended by the ESGO: the randomised LACC trial showed more recurrences and lower survival after minimally invasive surgery than after open abdominal surgery. Combining surgery and radiotherapy is also avoided, because the combination increases side effects.
In young women, the ovaries can often be preserved during surgery. Before radiotherapy, fertility preservation and surgically moving the ovaries out of the radiation field (ovarian transposition) may be offered.
After radical hysterectomy, difficulty emptying the bladder is common in the first few weeks and usually improves. After radiotherapy, vaginal dryness and narrowing, bowel or urinary problems, and menopause if the ovaries are irradiated may occur. These effects can be prevented and treated: do raise them at every appointment.
After treatment, regular follow-up is essential: see our article on follow-up after uterine cancer.
Would you like a medical opinion?Appointments in Paris 16th or 5th, or by video consultation.
Book an appointmentIt is rare but possible, because no test is perfect and some adenocarcinomas are hard to sample. That is why any bleeding after sex needs a check-up, even if your last screening was normal.
If the uterus and cervix were removed for a benign condition, cervical screening is no longer needed. If the operation was for a precancerous lesion or cancer, follow-up of the vaginal vault is still needed.
No. A positive HPV test only means the virus is present. Most of these infections clear on their own; a smear is then analysed on the same sample: if it is normal, the HPV test is repeated 1 year later; if it is abnormal, a colposcopy is offered.
For some small tumours, fertility-sparing surgery allows the uterus to be kept. In other cases, a fertility preservation consultation should be offered before treatment.
A question about your situation?Appointments at the practice or by video consultation, usually within one week to 10 days.
Book an appointmentGeneral information article: it does not replace a medical consultation. In an emergency, call 15 or 112 in France, or your local emergency number.